CoChat

Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy

Open access

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Abstract

Inhibitory antibodies to factor VIII (FVIII) are a major complication in the treatment of hemophilia A, affecting approximately 20% to 30% of patients. Current treatment for inhibitors is based on long-term, daily injections of large amounts of FVIII protein. Liver-directed gene therapy has been used to induce antigen-specific tolerance, but there are no data in hemophilic animals with pre-existing inhibitors. To determine whether sustained endogenous expression of FVIII could eradicate inhibitors, we injected adeno-associated viral vectors encoding canine FVIII (cFVIII) in 2 strains of inhibitor hemophilia A dogs. In 3 dogs, a transient increase in inhibitor titers (up to 7 Bethesda Units [BU]) at 2 weeks was followed by continuous decline to complete disappearance within 4-5 weeks. Subsequently, an increase in cFVIII levels (1.5%-8%), a shortening of clotting times, and a reduction (> 90%) of bleeding episodes were observed. Immune tolerance was confirmed by lack of antibody formation after repeated challenges with cFVIII protein and normal protein half-life. A fourth dog exhibited a strong early anamnestic response (216 BU), with slow decline to 0.8 BU and cFVIII antigen detection by 18 months after vector delivery. These data suggest that liver gene therapy has the potential to eradicate inhibitors and could improve the outcomes of hemophilia A patients.

Overview

Integrity signals

Registry

Crossref · 10.1182/blood-2010-06-288001

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 55 references

Research works printed but not linked: 1

  1. Roberts, 2001, Hemophilia A and hemophilia B., 1639

Cited by

See all 162

Metadata

Authors
Finn, J. D., Ozelo, M. C., Sabatino, D. E., Franck, H. W. G., Merricks, E. P., Crudele, J. M., Zhou, S., Kazazian, H. H., Lillicrap, D., Nichols, T. C., & Arruda, V. R.
Affiliations
  • Children's Hospital of Philadelphia (US)
  • Queen's University (CA)
  • University of Pennsylvania (US)
  • University of North Carolina at Chapel Hill (US)
Venue
Blood
Published
2010-12-23
Volume
116
Issue
26
Pages
5842-5848
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W1976158989
Cited by
157
References
52
Citations by year
2026: 5 · 2025: 3 · 2024: 13 · 2023: 5 · 2022: 7 · 2021: 7 · 2020: 15 · 2019: 11 · 2018: 14 · 2017: 13 · 2016: 12 · 2015: 14 · 2014: 10 · 2013: 9 · 2012: 8
FWCI
5.60
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • U.S. Public Health Service (R2414L063098)
  • Canadian Institutes of Health Research (MOP10912)
  • National Heart, Lung, and Blood Institute (HL084220, HL083017, R01HL084220, R24HL063098, R01HL083017)
Topics
  • Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
Keywords
hemophilia A, factor VIII inhibitors, neutralizing antibodies, liver-directed gene therapy, adeno-associated virus vectors, canine model, antigen-specific tolerance, inhibitor eradication, secondary immune response
MeSH terms
Adenoviridae, Animals, Dogs, Factor VIII, Flow Cytometry, Genetic Vectors, Half-Life, Hemophilia A, Immune Tolerance, Liver, Male, Tissue Distribution, Genetic Therapy, Antibodies, Neutralizing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. https://app.cochat.ai/papers/10.1182/blood-2010-06-288001
The paper
Finn, J. D., Ozelo, M. C., Sabatino, D. E., Franck, H. W. G., Merricks, E. P., Crudele, J. M., Zhou, S., Kazazian, H. H., Lillicrap, D., Nichols, T. C., & Arruda, V. R. (2010). Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood. https://doi.org/10.1182/blood-2010-06-288001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.